US20260109754
2026-04-23
Chemistry; metallurgy
C07K16/104
The document describes antibodies and antigen-binding fragments that target the spike protein of SARS-CoV-2. These antibodies are designed for various applications including prevention, treatment, and detection of SARS-CoV-2 infections. The antibodies can be used in different therapeutic contexts such as prophylaxis and post-exposure scenarios, providing a potential solution to combat the virus and its variants.
SARS-CoV-2, responsible for the COVID-19 pandemic, emerged in December 2019 and has caused significant global health challenges. The virus spreads through droplets from infected individuals and has a variable incubation period. While vaccines and treatments like Evusheld exist, their effectiveness against new variants is limited, highlighting the need for new therapeutic agents.
The antibodies in focus bind specifically to the spike protein of SARS-CoV-2. They are characterized by specific sequences identified as VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3. The document details compositions comprising one or more antibodies that either inhibit or bind to specific epitopes on the spike protein, enhancing their potential to neutralize the virus.
The described compositions demonstrate the ability to neutralize various SARS-CoV-2 variants, including BA.2.12.1, with significant potency. The antibodies are capable of reducing viral activity with low inhibitory concentrations, suggesting their effectiveness in managing infections from multiple viral strains.
The antibodies are primarily human-derived and include specific constant regions, such as IgG1 and IgGκ, which can incorporate mutations to enhance their function. These structural features are designed to improve the antibodies' stability and efficacy, making them suitable candidates for therapeutic development against SARS-CoV-2.